JPWO2021222625A5

JPWO2021222625A5 -

Info

Publication number: JPWO2021222625A5
Application number: JP2022566130A
Authority: JP
Publication date: 2024-04-24

Claims

1. A device for providing nicotine replacement therapy, comprising:
a processor, the processor comprising:
Determine the user's stop program;
determining a program intervention event based on a phase of the stopped program and a marker associated with the user;
A device configured to determine a modification to the stopped program based on the program intervention event.

The device of claim 1 , wherein the markers include at least one of cigarette count, nicotine data, user biomarkers, indicators of user behavior, craving detection, or smoking detection.

10. The device of claim 1, wherein the marker is at least one of heart rate, resting heart rate, heart rate variability, blood pressure, the user's temperature, respiration rate, oxygen saturation, skin temperature, carbon monoxide detection, or galvanic skin response.

10. The device of claim 1, wherein the phase is at least one of a cigarette reduction phase, a nicotine stabilization phase, or a nicotine reduction phase.

The device of claim 4 , wherein the program intervention event is at least one of a craving detection event, a smoking detection event, or a behavioral intervention event.

2. The device of claim 1 , wherein the modification to the cessation program based on the program intervention event includes a change to at least one of the rate of reduction of cigarettes, the duration of the phase, the speed of reducing cigarettes, the rate of reduction of the nicotine replacement therapy, or the speed of reducing the nicotine replacement therapy .

the marker is a cigarette consumption rate of the user, and the processor:
determining a rate of consumption of a nicotine formulation of said user;
determining a carbon monoxide saturation level of the user; and determining the program intervention event based on the user's cigarette consumption rate, the nicotine formulation consumption rate, and the carbon monoxide saturation level.
2. The device of claim 1 , configured to determine the program intervention event based on the phase of the suspension program and the cigarette consumption rate of the user by:

The processor,
determining a propensity to stop being stopped indicated by the program intervention event; and modifying a duration of the phase of the stopping program based on the propensity to stop being stopped.
The device of claim 7 , configured to determine the modification to the stopped program based on the program intervention event by:

1. A device for providing nicotine replacement therapy, comprising:
a processor, the processor comprising:
determining biomarkers associated with the user;
detecting nicotine craving using the biomarker associated with the user;
The device is configured to provide an intervention to the user based on the nicotine craving.

the biomarker is a first biomarker, and the processor:
determining a second biomarker associated with the user;
calculating a predictive value based on the first biomarker and the second biomarker, the predictive value indicating a probability that the user is experiencing nicotine craving; and determining that the user is experiencing nicotine craving when the predictive value exceeds a threshold.
10. The device of claim 9, configured to detect the nicotine craving using the first biomarker associated with the user by:

the biomarker is a galvanic skin response associated with the user, and the processor:
determining a heart rate of the user;
determining a skin temperature of the user; and detecting the nicotine craving using the galvanic skin response, the heart rate, and the skin temperature.
10. The device of claim 9, configured to detect the nicotine craving using the galvanic skin response associated with the user by

The processor,
determining a phase of a stop program associated with the user;
10. The device of claim 9, further configured to provide the intervention to the user based on the nicotine craving and the phase of the cessation program.

13. The device of claim 12, wherein the intervention is at least one of a behavioral intervention or a nicotine replacement therapy intervention, or the processor is configured to provide the intervention to the user based on the nicotine craving and the phase by sending a notification to the user, the notification including at least one of an indication that the user needs to dispense a dose of a nicotine formulation, behavioral therapy instructions, an indication of an action the user can take to reduce the nicotine craving, or an indication of the biomarker.

13. The device of claim 12, wherein the processor is further configured to determine modifications to the stopping program based on the intervention, the phase, and the biomarkers.

The processor,
determining the intervention, the phase, and a propensity to stop as indicated by the biomarkers;
The device of claim 12 , further configured to vary a duration of the phase based on the stopping tendency.

1. A device for providing nicotine replacement therapy, comprising:
a processor, the processor comprising:
determining a phase of a suspension program associated with the user;
determining a smoking detection event based on a biomarker associated with the user;
The device is configured to determine modifications to the suspension program based on the phase and the smoking detection event.

17. The device of claim 16, wherein the biomarker is at least one of a carbon monoxide level associated with the user, a heart rate of the user, a skin temperature of the user, or a galvanic skin response of the user.

the phase is a first phase, the processor
using the smoking detection events to determine a cigarette consumption rate of the user;
determining an increase to the duration of the first phase based on the rate of cigarette consumption;
determining that the increase to the duration of the first phase will exceed a threshold; and assigning the user to a second phase of the suspension program.
17. The device of claim 16, configured to determine the modification of the stopping program based on the first phase and the smoking detection event by:

17. The device of claim 16, wherein the processor is further configured to determine that a biomarker trend exceeds a threshold, the biomarker trend being associated with the biomarker.

the phase is a first phase, the processor
assigning the user to a second phase of the stopping program when the biomarker trend is determined to have exceeded the threshold;
determining a cigarette consumption rate using the smoking detection event; and determining a duration of the second phase of the suspension program based on the cigarette consumption rate.
20. The device of claim 19, configured to determine the modification of the stopping program based on the first phase and the smoking detection event by:

The processor,
determining a cigarette consumption rate using the smoking detection event when the biomarker trend is determined to exceed the threshold; and determining a duration of the phase of the cessation program based on the cigarette consumption rate.
20. The device of claim 19, configured to determine the modifications to the stopping program based on the phase and the smoking detection event by:

1. A device for providing nicotine replacement therapy, comprising:
a processor, the processor comprising:
determining a phase of a suspension program associated with the user;
determining a nicotine consumption detection event;
The device is configured to determine modifications to the cessation program based on the phase and the nicotine consumption detection event.

the phase is a first phase , the processor
assigning the user to a second phase of the cessation program when nicotine consumption is determined to be below the user's nicotine threshold;
determining a rate of nicotine consumption using the nicotine consumption detection event; and determining a duration of the second phase of the cessation program based on the rate of nicotine consumption.
23. The device of claim 22, configured to determine the modification of the cessation program based on the first phase and the nicotine consumption by: